This browser doesn't support Spotify Web Player. Switch browsers or download Spotify for your desktop.

PeerVoice Clinical Pharmacology Audio

By PeerVoice

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

  1. 1.
    Unmet Needs in Familial Mediterranean Fever (FMF): Real-Life Data, the Patient Perspective, and the Role of Anti–IL-1 Therapy10/28/2020
    59:06
  2. 2.
    Best Practices for MET Mutation Testing in NSCLC: The Role of the Oncologist and the Pathologist10/25/2020
    16:37
  3. 3.
    Novel Therapies for Patients With DLBCL: What Does the Future Hold?10/22/2020
    1:04:21
  4. 4.
    New Targets in Heart Failure: Congress Updates on SGLT2 Inhibitors10/21/2020
    12:32
  5. 5.
    Evaluating the Evidence for SGLT2 Inhibition in CKD10/19/2020
    19:42
  6. 6.
    Halting the Cascade of Chronic Kidney Disease: Can We Catch Patients Before They Fall?10/15/2020
    36:03
  7. 7.
    A Look at Emerging SMA Outcomes: Highlights of CureSMA 202010/05/2020
    9:56
  8. 8.
    A Look at Emerging SMA Outcomes: Highlights of EAN 202010/02/2020
    9:52
  1. 9.
    Deciphering the Role of MET Alterations in Advanced NSCLC: Unmet Needs09/28/2020
    15:42
  2. 10.
    New Targets in IBD: Focus on IL-2309/23/2020
    18:11
  3. 11.
    Are All Biologics the Same? Optimal Treatment Strategies for Patients With Inflammatory Bowel Disease09/21/2020
    21:28
  4. 12.
    New Targets, New Hope in SMA: A 2020 Congress Coverage09/18/2020
    8:18
  5. 13.
    Practice-Changing Perspectives in CMV: Managing the Burden in HSCT and SOT09/14/2020
    25:45
  6. 14.
    Transforming the Treatment of Acute Hepatic Porphyria 09/11/2020
    17:34
  7. 15.
    Hidden in Plain Sight: Uncovering Truncal Acne09/09/2020
    13:03
  8. 16.
    Extending Your Interdisciplinary Understanding of IL-6R Inhibitors in Rheumatoid Arthritis09/07/2020
    1:15:18
  9. 17.
    New Targets, New Hope in SMA: A 2020 Congress Coverage09/04/2020
    27:48
  10. 18.
    Identifying Barriers to and Developing Opportunities for Rotavirus Vaccination08/31/2020
    17:53
  11. 19.
    Weighing Evidence and Perspectives on JAK Inhibitors in Psoriatic Arthritis: Can We Do More for Patients?08/21/2020
    18:31
  12. 20.
    "Optimising the Use of JAK Inhibitors in RA: Translating the Latest Evidence Into Today’s Clinical Practice"08/17/2020
    23:26
  13. 21.
    Talking Meningococcal B Vaccines: Who Needs Protecting Now?08/12/2020
    20:01
  14. 22.
    Early Disease Control in Inflammatory Bowel Disease: Integrating the Latest Evidence for Better Outcomes07/27/2020
    18:50
  15. 23.
    Managing Youth-Onset Type 2 Diabetes: What Paediatricians Need to Know07/22/2020
    19:47
  16. 24.
    Patient Scenarios in Rheumatoid Arthritis: Optimising Remission With JAK Inhibitors07/13/2020
    16:56
  17. 25.
    Defining a Patient-Centred Approach to Non-Metastatic Castration-Resistant Prostate Cancer07/01/2020
    1:19:30
  18. 26.
    Treatment Update in CML: What’s New, and What Does it Mean for Patients?06/26/2020
    20:48
  19. 27.
    Hiding in Plain Sight: Identifying Patients at Risk for NASH06/19/2020
    24:34
  20. 28.
    Managing Complicated Cases in Type 2 Diabetes06/08/2020
    14:24
  21. 29.
    Practical Lessons From Real-World Evidence on CDK 4/6 Inhibitors in Metastatic Breast Cancer05/18/2020
    22:01
  22. 30.
    Changing Strategies for Changing Times: Optimising Use of Targeted Alpha Therapies for Advanced Prostate Cancer05/13/2020
    23:32
  23. 31.
    Raising the Caliber of Non-Metastatic CRPC Care: Introducing Quality of Life Into the Equation05/08/2020
    37:42
  24. 32.
    How Much Is Too Much? Weighing the Benefits and Limitations of Corticosteroids for IBD04/20/2020
    17:57
  25. 33.
    Individualising Stroke Prevention in Older Adults With Atrial Fibrillation (How I Treat)04/15/2020
    14:27
  26. 34.
    Acute Polyneuropathy With Abdominal Pain: Could It be Acute Hepatic Porphyria?04/13/2020
    15:02
  27. 35.
    Building on the Pillars of IBD Treatment: Early Intervention, Treat-to-Target, and Tight Control04/06/2020
    21:16
  28. 36.
    Imagining a World Without Hepatitis C Virus: A Call to Action04/02/2020
    10:03
  29. 37.
    Individualising HIV Care to Optimise Outcomes: Clinical Points of View and Practical Considerations for Switching ART03/27/2020
    23:23
  30. 38.
    Patient Scenarios in Rheumatoid Arthritis: Optimising Remission With JAK Inhibitors03/23/2020
    16:56
  31. 39.
    Elimination of Hepatitis C: Simple Changes for Comprehensive Results02/24/2020
    19:58
  32. 40.
    Evolving the Treatment Paradigm in HER2-Positive Breast Cancer: Are New Options on the Horizon?02/21/2020
    15:22
  33. 41.
    Talking About Pertussis Vaccine in Pregnancy: Managing Women’s Expectations02/14/2020
    14:00
  34. 42.
    A Topical Approach to Mild-to-Moderate Atopic Dermatitis: Finding the Right Fit for Patients of All Ages02/12/2020
    16:58
  35. 43.
    Cracking the Code for Fracture Risk: Improving the Early Identification of Patients02/10/2020
    22:30
  36. 44.
    Staying Ahead of Perianal Fistulas in Crohn's Disease: A Focused Approach to Management01/10/2020
    25:21
  37. 45.
    "Managing Stroke Risk Due to Atrial Fibrillation in Older Patients: Expert Perspectives"01/08/2020
    21:30
  38. 46.
    Managing Lipid-Related Cardiovascular Risk: What We Know Now01/06/2020
    19:23
  39. 47.
    Evolution of Paroxysmal Nocturnal Haemoglobinuria: Complementing Current Approaches to Management12/27/2019
    30:25
  40. 48.
    Improving Outcomes in CSCC: What Dermatologists Need to Know12/23/2019
    1:11:55
  41. 49.
    Is It More Than Just Depression? Identifying and Managing Comorbid Depression and ADHD12/13/2019
    22:43
  42. 50.
    Immuno-oncology for mRCC: Considerations for a Combination Approach in the First-Line Setting12/04/2019
    18:34
  43. 51.
    Recognising and Addressing Burden of Disease in Adolescents With Moderate-to-Severe AD12/02/2019
    19:33
  44. 52.
    Heading Toward a More Successful Approach to Migraine Management11/27/2019
    13:40
  45. 53.
    Choose Your Own HS Adventure: Going Beyond Current Guidelines11/15/2019
    57:29
  46. 54.
    Setting a Path for Success in Type 2 Diabetes: What We Know Now11/08/2019
    1:11:20
  47. 55.
    Warming Up to Novel Approaches for Primary Cold Agglutinin Disease: Strategies for Correct Diagnosis and Optimal Treatment11/04/2019
    16:08
  48. 56.
    Evaluating the Latest Data in Ulcerative Colitis11/01/2019
    17:29
  49. 57.
    PARP Inhibitors for Ovarian Cancer: Making the Right Choices at the Right Times10/30/2019
    9:52
  50. 58.
    Getting at the Heart of Comprehensive Disease Control in Type 2 Diabetes: What’s New?10/23/2019
    1:17:18
  51. 59.
    Making Heads and Tails of CGRP-Targeting Therapies: How Will They Fit Into Migraine Prevention Strategies?10/21/2019
    19:00
  52. 60.
    Advancing Care in Neurology Practice: Migraine-Specific Preventive Treatments10/18/2019
    21:49
  53. 61.
    Paving the Way to Better Outcomes in EGFR-Mutant NSCLC: Time to Take a Step Further?10/16/2019
    1:07:42
  54. 62.
    Understanding Hypercapnia in Acute Respiratory Distress Syndrome: The Quest for Optimal Patient Outcomes09/13/2019
    12:48
  55. 63.
    IL-6 Receptor Inhibition in RA: New Perspectives in Optimal Patient Care08/26/2019
    1:13:39
  56. 64.
    Managing Perianal Fistulas in Crohn’s Disease: Can We Do More? 08/14/2019
    31:45
  57. 65.
    Maximising the Long-Term Treatment Plan for Unresectable Hepatocellular Carcinoma: A Sequential Approach to Improving Patient Outcomes07/08/2019
    20:47
  58. 66.
    The Power of Personalised Medicine: CAR-T Immunotherapy for Treatment of Aggressive Large B-Cell Lymphoma07/05/2019
    21:54
  59. 67.
    Acute Kidney Injury After Cardiac Surgery: Optimising Outcomes in High-Risk Patients06/19/2019
    17:35
  60. 68.
    Meeting the Clinical Challenge: Individualising Anticoagulation for Patients With AF and ACS06/14/2019
    23:25
  61. 69.
    Optimising the Treatment of mRCC From the Start: Evaluating the Impact of Evolving First-Line Strategies06/10/2019
    16:40
  62. 70.
    Teaming Up to Improve Outcomes in Immunology: The Importance of an Integrated Approach to Disease Control06/03/2019
    19:13
  63. 71.
    Elimination of Hepatitis C: Simple Changes for Comprehensive Results05/31/2019
    19:59
  64. 72.
    Beyond Positive and Negative HER2 Status: Defining HER2 Levels in Breast Cancer05/27/2019
    19:30
  65. 73.
    Targeting Remission in Auto-Inflammatory Diseases With Anti─IL-1β05/24/2019
    46:04
  66. 74.
    Imagining a World Without Hepatitis C Virus: A Call to Action05/22/2019
    10:03
  67. 75.
    Aiming Higher in Advanced Cutaneous Squamous Cell Carcinoma: Experts Evaluate the Evidence for Immunotherapy05/17/2019
    28:35
  68. 76.
    Emerging ‘Tumour-Agnostic’ Oncology Treatment: The Role of the Pathologist in Identifying Neurotrophic Tyrosine Kinase Gene Fusions05/03/2019
    25:58
  69. 77.
    Merging Clinical Trial Results and Reality: The Real-World Implications of Androgen Receptor Antagonists for Non–Metastatic Castration-Resistant Prostate Cancer04/29/2019
    29:06
  70. 78.
    A Case for Clarity: Putting the Latest Recommendations for IPF Into Context04/22/2019
    10:09
  71. 79.
    Should We Be Treating Ulcerative Colitis as a Progressive Disease?03/29/2019
    15:50
  72. 80.
    Learning From the Literature: The Latest Evidence on JAK Inhibitors for RA03/20/2019
    16:27
  73. 81.
    Optimising Outcomes for Young Women With Breast Cancer: The Role of Adjuvant Ovarian Suppression03/15/2019
    21:05
  74. 82.
    A Closer Look at Safety of Glucose-Lowering Therapy02/27/2019
    18:46
  75. 83.
    Managing Patients With HER2-Low Breast Cancer02/19/2019
    14:29
  76. 84.
    Is There a Cardio-Oncologist in the House? Managing Risk for VTE and Stroke Due to AF in Patients With Cancer02/07/2019
    19:41
  77. 85.
    Do You Know JAK? Updates From Chicago on Rheumatoid Arthritis Management02/05/2019
    18:59
  78. 86.
    Spotlight on Disease Burden and Quality of Life in Atopic Dermatitis: Are We Missing the Big Picture?01/07/2019
    11:38
  79. 87.
    A High Index of Suspicion: The Key to Early Diagnosis and Treatment of Atypical Haemolytic Uraemic Syndrome01/02/2019
    22:16
  80. 88.
    Developing a Selective Approach to Prevent Pain Crisis in Sickle Cell Disease: Can Emerging Therapies Pave the Way?12/17/2018
    15:18
  81. 89.
    Expert Perspectives: Weighing the Evidence for Current and Emerging Therapies in the Management of Advanced Renal Cell Carcinoma12/14/2018
    33:09
  82. 90.
    Current Clinical Challenges in CF Management: Review of the Evidence by the Experts12/11/2018
    25:10
  83. 91.
    Debated Issues in the Prevention of Severe RSV in Infants12/07/2018
    32:36
  84. 92.
    Biomarkers in Lung Cancer: Targeting the Right Patient With the Right Therapy11/26/2018
    1:14:45
  85. 93.
    How a New Understanding of Severe Asthma Is Changing Treatment Paradigms11/23/2018
    19:37
  86. 94.
    Improving Outcomes in Type 2 Diabetes: Focus on Cardiovascular and Renal Safety11/06/2018
    1:13:39
  87. 95.
    Stroke Prevention in Atrial Fibrillation: Lessons from Real-World Studies10/24/2018
    21:59
  88. 96.
    Ticking All the Boxes: A Multidisciplinary Approach to Hidradenitis Suppurativa10/17/2018
    1:10:30
  89. 97.
    Navigating the Road to Psoriasis Control in Women: Strategies to Optimise the Reproductive Journey10/15/2018
    1:06:51
  90. 98.
    Endotyping Severe Asthma: For Which Patients and Why?10/12/2018
    16:41
  91. 99.
    Forging a Path to RA Treatment: Exploring the Potential for IL-6 Inhibitors10/08/2018
    16:23
  92. 100.
    Keeping the Future in Sight in Acute Schizophrenia Care: The Role of Long-Acting Injectables10/03/2018
    8:06
  93. 101.
    Targeting IL1-β Toward Remission in Auto-Inflammatory Diseases – Expert Perspectives on Recent Clinical Data10/01/2018
    54:37
  94. 102.
    Paroxysmal Nocturnal Haemoglobinuria: Complementing Current Knowledge To Improve Outcomes09/28/2018
    28:08
  95. 103.
    Best Practices for Use of Proteasome Inhibitors in the Treatment of Relapsed/Refractory Multiple Myeloma09/24/2018
    19:11
  96. 104.
    Learning From the Literature: New Data for Improving CF Management and Patient Outcomes09/17/2018
    20:05
  97. 105.
    Spotlight on Adult ADHD and Substance Use Disorder: Identifying and Managing Difficult Cases09/10/2018
    15:54
  98. 106.
    Type 2 Inflammation in Severe Asthma: What Does It Mean Today?09/05/2018
    14:54
  99. 107.
    Balancing Safety With Stroke Prevention in High-Risk Patients With AF08/31/2018
    15:12
  100. 108.
    Conversations on Steps to Biologic Therapy for Atopic Dermatitis: Patient and Dermatologist Insights for European Practice08/29/2018
    17:51
  101. 109.
    Best Practices in Managing CML08/17/2018
    17:59
  102. 110.
    Clinical Updates: New Pathways and Strategies in Small-Cell Lung Cancer07/04/2018
    19:09
  103. 111.
    Exploring Treatment Choices in Crohn’s Disease: Using Current Evidence to Optimize Outcomes07/02/2018
    16:46
  104. 112.
    Getting Under the Skin in Atopic Dermatitis: Evolving Treatment Approaches06/26/2018
    18:00
  105. 113.
    Newer Targeted Therapies for Rheumatoid Arthritis: Weighing the Pros and Cons06/19/2018
    14:50
  106. 114.
    Tips and Tricks in Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis06/15/2018
    25:47
  107. 115.
    An Integrative Approach to the Management of Spondyloarthritis: Improving Clinical Outcomes and Quality of Life06/13/2018
    24:16
  108. 116.
    Improving Clinical Management of Patients with Heart Failure06/01/2018
    15:08
  109. 117.
    Locally Advanced BCC: Selecting the Right Option to Optimise Outcomes in Your Patients05/11/2018
    18:38
  110. 118.
    Improving the Long-Term Treatment Plan for Patients With Metastatic Pancreatic Cancer: Insights From San Francisco05/09/2018
    8:25
  111. 119.
    Conundrums in Ulcerative Colitis: Matching the Right Biologic to the Right Patient05/04/2018
    16:16
  112. 120.
    The Treatment Plan for Patients With Nonmetastatic Prostate Cancer in Canada: Optimizing the Journey From The Beginning05/03/2018
    26:10
  113. 121.
    Emerging Biomarkers in Small-Cell Lung Cancer: A New Era04/30/2018
    16:44
  114. 122.
    Expert Perspectives on Managing Complex Patients With Spondyloarthritis04/27/2018
    21:29
  115. 123.
    Considering the Possibility of Psoriatic Arthritis in Patients With Psoriasis04/25/2018
    16:02
  116. 124.
    Cardiovascular and Renal Safety in Type 2 Diabetes: What Clinicians Need to Know04/20/2018
    20:44
  117. 125.
    Protecting Adolescents and Adults From Vaccine Preventable Bacterial Diseases: A Look at Serogroup B Meningococcal Disease and Pneumococcal Diseases04/18/2018
    16:54
  118. 126.
    Treating Rheumatoid Arthritis and Spondyloarthritis to Target: What Are We Missing in Clinical Practice?04/16/2018
    21:27
  119. 127.
    Looking Beyond the Skin and Joints in Psoriatic Arthritis: A Comprehensive Approach to Improving Patient Outcomes04/13/2018
    17:26
  120. 128.
    Improving Outcomes in Later Lines of Therapy for Metastatic Colorectal Cancer04/11/2018
    18:48
  121. 129.
    New Strategies, New Targets: The Evolving Landscape in Driver-Mutation–Positive Advanced NSCLC04/09/2018
    11:04
  122. 130.
    Von der Krankheitsentstehung zu klinischen Strategien für autoinflammatorische und Autoimmunerkrankungen: Welche Rolle spielen Interleukine?04/06/2018
    40:51
  123. 131.
    Enthesitis in Psoriatic Arthritis and Spondyloarthritis: Targeting Pathophysiologic Mechanisms to Optimise Patient Management04/05/2018
    21:05
  124. 132.
    Defining the Optimal Respiratory Syncytial Virus Infection Management Strategy: Applying Health Economics to Improve Patient Outcomes04/02/2018
    19:07
  125. 133.
    Addressing the Management Challenges of JIA-Associated Uveitis: From Screening to Treatment03/19/2018
    17:32
  126. 134.
    A New Paradigm Shift in IBD? Clinical Advances in Applying a Treat-to-Target Strategy01/06/2018
    17:53
  127. 135.
    Managing Patients With Overactive Bladder in Canada: Evaluating Recent Evidence12/29/2017
    17:07

Listen to PeerVoice Clinical Pharmacology Audio now.

Listen to PeerVoice Clinical Pharmacology Audio in full in the Spotify app